131I treatment in thyroid cancer patients may induce side effects, including extrathyroidal
cancer and leukemia. There are still some uncertainties concerning parameters that may …

There is no consensus on the amount of 131I for treatment of patients with well-differentiated
thyroid carcinoma; usual amounts vary widely. Body retention of 131I has been shown to be …

A dose limit–based criterion was proposed to authorize hospital discharge of thyroid
carcinoma patients treated with 131I. Evaluation of accumulated doses to determine the …

The aim of this study was to investigate the influence of the diagnostic administration of 74
MBq 131I on subsequent uptake of therapeutic radioiodine in thyroid cancer patients …

The oral administration of radioactive 131 I is a standard treatment for thyroid carcinoma.
One consideration for this therapy is assuring that other people do not receive significant …

Background: In medical applications of radioisotopes, for calculations of whole body doses
and radiation safety applications, there is a need to estimate radioactive body burden. Local …

Nuclear medicine procedures that use 131 I activity represent significant sources of potential
absorbed dose to medical staff, volunteers, and the general public. The potential exposures …

This short review focuses on two questions commonly asked about 131I therapy of thyroid
cancer. The first relates to radiation dosimetry. What percentage of 131I uptake is needed for …

Awidely accepted therapy is 131I for patients with hyperthyroidism caused by Graves'
disease, toxic nodular disease, euthyroid multinodular goiters, and differentiated thyroid …

The Code of Federal Regulations, title 10, part 35.75 (10CFR35. 75), provides greater
latitude and flexibility in the dosing and management of outpatients treated with therapeutic …